Crescent Biopharma - Potential To Initiate First CR-001 Phase 3 Study In Early 2028

By Reuters News

Oct 15 (Reuters) - Crescent Biopharma, Inc. CBIO.O:

  • CRESCENT BIOPHARMA - POTENTIAL TO INITIATE FIRST CR-001 PHASE 3 STUDY IN EARLY 2028

  • CRESCENT BIOPHARMA - MULTIPLE SAC-TMT PLUS CR-001 PHASE 2 STUDIES ONGOING IN OVER 700 PATIENTS; DATA MID-2027

  • CRESCENT BIOPHARMA -ON TRACK TO REPORT INITIAL MONOTHERAPY DATA FROM ASCEND IN Q1 2027, INCLUDING ANTITUMOR RESPONSE FOR FIRST-LINE NSCLC COHORT

  • CRESCENT BIOPHARMA - APOLLO PHASE 1/2 TRIAL OF CR-002 TO COMMENCE DOSING THIS QUARTER; DATA H2 2027

  • CRESCENT BIOPHARMA - PHASE 1/2 TRIAL OF CR-003 ONGOING IN CHINA; INITIAL DATA EXPECTED Q1 2027

Further company coverage: CBIO.O

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk